China Resources Double‑Crane Pharmaceutical Co., Ltd. (SHA: 600062) announced that its controlled subsidiary, China Resources Double‑Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd. (“Double‑Crane Xiangzhong”), has received the “Chemical API Marketing Application Approval Notice” from China’s National Medical Products Administration (NMPA) for Vortioxetine Hydrobromide, an active pharmaceutical ingredient (API) used in the treatment of adult depression. The approval — notice No. 2026YS00931, registration No. Y20250000126 — complements the subsidiary’s already-approved vortioxetine hydrobromide tablets (5 mg and 10 mg), extending the group’s vertically integrated position in the antidepressant market.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Chemical API marketing application approval (domestic production) |
| Product | Vortioxetine Hydrobromide API (3 kg/bag packaging specification) |
| Registration No. | Y20250000126 |
| Notice No. | 2026YS00931 |
| Approval Date | 29 Sep 2026 |
| Manufacturer | China Resources Double‑Crane Xiangzhong Pharmaceutical (Hunan) Co., Ltd. |
| CDE Platform Status | “A” on the CDE API/excipient/packaging registration information platform |
| Cumulative R&D Investment | RMB 9.4891 million (unaudited) |
API Profile & Approval Pathway
- Product: Vortioxetine Hydrobromide, the API form of vortioxetine — an antidepressant indicated for the treatment of adult depression.
- Regulatory Basis: Approved following review under the Drug Administration Law of the People’s Republic of China, with the NMPA concluding that the product meets drug registration requirements; quality standards, labeling, and manufacturing process to be executed as attached to the notice.
- Review Timeline: Application submitted to the Center for Drug Evaluation (CDE) on 15 Feb 2025; publicized registration on 28 Feb 2025; approval notice issued 29 Sep 2026 — a review cycle of approximately 19 months.
- Downstream Formulations: Double‑Crane Xiangzhong’s vortioxetine hydrobromide tablets have already received Drug Registration Certificates — 10 mg on 27 May 2025 and 5 mg on 10 Jun 2026 — meaning the group now controls both the API and finished dosage forms.
- Commercialization Condition: The API may be produced and sold to the domestic market after passing a GMP compliance inspection.
Market Context – Vortioxetine API Landscape
- Mechanism Background: Vortioxetine is a multimodal antidepressant — a serotonin reuptake inhibitor with additional serotonergic receptor modulation — widely used for major depressive disorder in adults. (Domain background.)
- Competitive Registration Field: A total of 26 manufacturers (including Double‑Crane Xiangzhong) are currently registered for vortioxetine hydrobromide on the CDE API/excipient/packaging registration information platform — a moderately crowded domestic API field.
- Data Transparency Limits: The company stated it cannot yet ascertain international or domestic production and sales data for this API through public channels; market size figures were not disclosed.
- Strategic Rationale: The approval is expected to further enrich the company’s product line and enhance market competitiveness, per the announcement.
Market Impact & Outlook
- Vertical Integration: With API approval now in hand alongside the 5 mg and 10 mg tablet registrations, China Resources Double‑Crane secures supply-chain self-sufficiency for its vortioxetine franchise — protecting formulation margins and supply continuity.
- Capital Efficiency: The program’s cumulative R&D investment of RMB 9.4891 million (unaudited) reflects the comparatively modest cost base of API development versus novel drug discovery.
- Group Portfolio Fit: The approval advances the state-owned China Resources group’s CNS/psychiatry product line under its Double‑Crane pharmaceutical platform.
- Competitive Positioning: Among 26 registered domestic producers, differentiation will hinge on GMP execution, cost position, and captive supply to the group’s own tablet production.
- Next Steps: GMP compliance inspection ahead of domestic production and sales; no timeline for the inspection or commercial launch was disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding China Resources Double‑Crane’s vortioxetine hydrobromide API, including the anticipated GMP compliance inspection, domestic commercialization, and portfolio impact. API approval does not guarantee commercial outcomes. Actual results may differ due to risks including inspection timing, competitive supply dynamics among 26 registered producers, downstream tablet demand, and market conditions. The company has disclosed that it cannot currently obtain domestic or international production and sales data for the API.-Fineline Info & Tech
